Dubai Telegraph - Highly awaited Alzheimer's drug hit by delays

EUR -
AED 4.100593
AFN 77.415121
ALL 99.401365
AMD 432.532608
ANG 2.013835
AOA 1036.608223
ARS 1074.850088
AUD 1.637751
AWG 2.009578
AZN 1.914553
BAM 1.956452
BBD 2.256112
BDT 133.534528
BGN 1.965976
BHD 0.420727
BIF 3238.922016
BMD 1.116432
BND 1.442855
BOB 7.721436
BRL 6.05754
BSD 1.117453
BTN 93.463755
BWP 14.702639
BYN 3.656854
BYR 21882.072714
BZD 2.252301
CAD 1.514161
CDF 3205.277492
CHF 0.944965
CLF 0.037663
CLP 1039.241885
CNY 7.876433
CNH 7.87576
COP 4650.21956
CRC 578.846357
CUC 1.116432
CUP 29.585455
CVE 110.298816
CZK 25.095144
DJF 198.982787
DKK 7.459215
DOP 67.07696
DZD 147.738594
EGP 54.183251
ERN 16.746484
ETB 128.59903
FJD 2.455368
FKP 0.850229
GBP 0.839942
GEL 3.047851
GGP 0.850229
GHS 17.599632
GIP 0.850229
GMD 76.471646
GNF 9655.133082
GTQ 8.637648
GYD 233.733753
HKD 8.697404
HNL 27.718995
HRK 7.590635
HTG 147.256466
HUF 394.390564
IDR 16847.577163
ILS 4.213968
IMP 0.850229
INR 93.351322
IQD 1463.774994
IRR 46993.458659
ISK 152.291985
JEP 0.850229
JMD 175.556968
JOD 0.791213
JPY 158.635534
KES 144.142696
KGS 94.087347
KHR 4535.390482
KMF 492.737717
KPW 1004.78842
KRW 1485.278958
KWD 0.340423
KYD 0.931202
KZT 535.183667
LAK 24674.006694
LBP 100063.3742
LKR 340.140375
LRD 223.480517
LSL 19.469018
LTL 3.296534
LVL 0.675319
LYD 5.32268
MAD 10.836419
MDL 19.499328
MGA 5034.588624
MKD 61.635001
MMK 3626.1285
MNT 3793.636842
MOP 8.970411
MRU 44.23275
MUR 51.210562
MVR 17.148494
MWK 1937.602717
MXN 21.565285
MYR 4.675062
MZN 71.284504
NAD 19.469018
NGN 1805.851919
NIO 41.123344
NOK 11.71286
NPR 149.533808
NZD 1.788076
OMR 0.42978
PAB 1.117453
PEN 4.195005
PGK 4.43644
PHP 62.007205
PKR 310.777563
PLN 4.276075
PYG 8722.752395
QAR 4.073749
RON 4.97404
RSD 117.056828
RUB 102.904402
RWF 1504.874851
SAR 4.18934
SBD 9.274133
SCR 15.206594
SDG 671.536448
SEK 11.338824
SGD 1.44022
SHP 0.850229
SLE 25.507466
SLL 23411.020982
SOS 638.607227
SRD 33.328879
STD 23107.894155
SVC 9.777173
SYP 2805.069528
SZL 19.454139
THB 36.967864
TJS 11.878054
TMT 3.907513
TND 3.384438
TOP 2.623388
TRY 38.061582
TTD 7.595465
TWD 35.626914
TZS 3044.960797
UAH 46.305211
UGX 4149.309281
USD 1.116432
UYU 45.904073
UZS 14235.619446
VEF 4044334.590166
VES 41.034973
VND 27425.15899
VUV 132.545083
WST 3.123178
XAF 656.164047
XAG 0.035914
XAU 0.000431
XCD 3.017214
XDR 0.828161
XOF 656.164047
XPF 119.331742
YER 279.470913
ZAR 19.560006
ZMK 10049.230311
ZMW 29.080046
ZWL 359.490739
  • BCC

    7.6300

    144.69

    +5.27%

  • GSK

    -0.8100

    41.62

    -1.95%

  • CMSC

    0.0650

    25.12

    +0.26%

  • RIO

    2.2700

    65.18

    +3.48%

  • NGG

    -1.2200

    68.83

    -1.77%

  • BTI

    -0.3100

    37.57

    -0.83%

  • AZN

    0.3200

    78.9

    +0.41%

  • SCS

    -0.8000

    13.31

    -6.01%

  • BP

    0.3300

    32.76

    +1.01%

  • BCE

    -0.4200

    35.19

    -1.19%

  • JRI

    -0.0400

    13.4

    -0.3%

  • RBGPF

    60.5000

    60.5

    +100%

  • CMSD

    0.0300

    25.01

    +0.12%

  • RYCEF

    -0.0200

    6.93

    -0.29%

  • RELX

    0.7600

    48.13

    +1.58%

  • VOD

    -0.1700

    10.06

    -1.69%

Highly awaited Alzheimer's drug hit by delays
Highly awaited Alzheimer's drug hit by delays / Photo: PHILIPPE LOPEZ - AFP

Highly awaited Alzheimer's drug hit by delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Text size:

Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial -- but there was also a high rate of side effects, including deaths.

The Food and Drug Administration (FDA) "has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab," the company said in a statement Friday.

The regulator told the Indiana-based company it would convene a new meeting of experts, but hadn't provided a firm date. "As a result, the timing of expected FDA action on donanemab will be delayed beyond the first quarter of 2024."

"We are confident in donanemab's potential to offer very meaningful benefits to people with early symptomatic Alzheimer's disease," said Anne White, the company's executive vice president.

She added the FDA's decision to have a new meeting was "unexpected," but "We will work with the FDA and the stakeholders in the community to make that presentation and answer all questions."

Donanemab is an intravenously injected antibody that targets the build up beta-amyloid, a protein found in the brains of many patients with Alzheimer's.

Another anti-amyloid therapy called Leqembi, which was developed by Eisai of Japan and Biogen of Massachusetts, was granted full approval by the FDA last July and is now accessible through government-run health insurance for the elderly called Medicare.

- Slows decline, but risky -

In a paper published in the Journal of the American Medical Association last year, researchers found donanemab slowed cognitive and functional decline in patients who have early symptoms of the disease.

Forty-seven percent of those who received the drug showed no signs of cognitive decline after one year of treatment, compared to 29 percent who received a placebo.

Serious adverse events, including brain bleeds, occurred in 17.4 percent of those who received donanemab and 15.8 percent of those who received a placebo.

There were also four deaths: three in the donanemab group and one in the placebo group, but all the fatalities were considered a result of the treatment they received.

The trial recruited participants aged 60 to 85 with early symptomatic Alzheimer's, either mild cognitive impairment or Alzheimer's disease with mild dementia.

The news comes after the first Alzheimer's drug to be approved was pulled from the market in January.

The FDA awarded accelerated approval to Aduhelm in June 2021, a decision that was contentious at the time because the agency overruled its own independent advisors, who found there was insufficient evidence of benefit.

Biogen, which co-developed Aduhelm with Eisai, said it was discontinuing Aduhelm to focus its efforts of Leqembi.

Alzheimer's is the most common form of dementia. More than one in nine people over 65 develop the condition, which worsens over time, robbing them of their memories and independence, according to the US Alzheimer's Association.

Y.Sharma--DT